期刊文献+

脑膜炎球菌病的流行病学及疫苗(续) 被引量:4

The epidemiology of meningococcal disease and vaccines (continued)
原文传递
导出
摘要 脑膜炎球菌是唯一能导致全球流行性脑脊髓膜炎(流脑)流行的病因。全球范围内90%的病例是由A、B、C、Y和W135群所致。欧美国家主要流行菌群为B、C和Y群;亚洲和非洲主要是A、C和W135群。A、C、Y和W135群多糖疫苗能有效控制流脑暴发,但由于在婴儿中免疫原性差,应用并不广泛。发达国家在引进C群结合疫苗后,C群流脑发病数迅速下降。A、C、Y和W135群结合疫苗的研制成功有望控制这些群导致的流脑流行。以外膜囊、外膜蛋白和基因组来源的表面蛋白为目标的B群疫苗研究取得不同程度的进展。 Neisseria meningitides (Nm) is the only cause of endemic meningococcal disease worldwide. Globally, 90% of Nm diseases are caused by groups A, C, Y and W135. GroUps B, C and Y are responsible for the majority of cases of Nm disease in Europe and America, and groups A, C and W135 predominate in Asia and Africa. Polysaccharide vaccines against groups A, C, Y and W135 are effective for control of Nm disease outbreak, but have not been used widely due to poor immunogenicity in infants. The number of cases of group C meningitis has been reduced rapidly after the introduction of group C conjugate vaccines in industrialized countries. Conjugate vaccines against groups A, C, Y and W135 have the potential to control Nm diseases caused by these groups. In addition, research on group B Nm vaccine targeted at outer membrane vesicle, outer membrane proteins and surface antigens originated from the genome have also been made varying progress.
出处 《国际生物制品学杂志》 CAS 2012年第3期134-138,共5页 International Journal of Biologicals
关键词 奈瑟球菌 脑膜炎 脑膜炎 脑膜炎双球菌感染 流行病学 疫苗 Neisseria meningitidis Meningitis Meningococcal infections Epidemiology Vaccines
  • 相关文献

参考文献27

  • 1De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec [J]. JAMA, 2001, 285(2) : 177-181.
  • 2Committee on Infectious Diseases. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients [ J ]. Pediatrics, 2005, 116 ( 2 ) : 496-505.
  • 3Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction [J]. Lancet, 2004, 364(9,$31):365-367.
  • 4UK Health Protection Agency. All laboratory confirmed cases of invasive meningococcal disease by serogroup, age and epidemiologieal year [ DB/OI,]. (2009-07-02) [2011-04-27 I. http://www, hpa. org. uk/webw/HPAweb&HPAwebStandard/ HPAweb C/1234859710351? p = 1201094595391.
  • 5Gray S J, Trotter CL, Ramsay ME, et al. Epidemiology of meningoeoccal disease in England and Wales 1993/94 to 2003/ 04 : contribution and experiences of the Meningoeoeeal Reference Unit E JI. J Med Merobiol, 2006, 55(7):887-896.
  • 6Maiden MC, Ibarz-Pav6n AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity [J]. J Infect Dis, 2008, 197(5) :737-743.
  • 7Bettinger JA, Scheifele DW, Le Saux N, et al. The impact of childhood meningococcal semgroup C conjugate vaccine programs in Canada [J], Pediatr hffect Dis J, 2009, 28(3) :220-224.
  • 8De Wals P, Deceuninck G, Boulianne N, et at. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine [ J]. JAMA, 2004, 292(20) :2491-2494.
  • 9De Greeff SC, Ruijs H, Timen A , et al. First effects of meningococcal C vaccination campaign in the Netherlands [ J ]. Eurosurveillance Weekly, 2003, 147 (23) : 1132-1135.
  • 10Centers for Disease Control and Prevention ( CDC ). Guillain-Barr6 syndrome among recipients of Menaetra meningococcal conjugate vaccine--United States, June-July 2005 J ]. MMWR Morb Mortal Wkly Rep, 2005, 54(40) :1023-1025.

同被引文献29

  • 1覃艳春,陆金兰,陆吉利,韦启后.免疫血清制备方法改良初探[J].右江民族医学院学报,2005,27(6):892-892. 被引量:11
  • 2肖丽君,方艳辉,程露阳,孔健.脑膜炎奈瑟菌疫苗研制进展[J].微生物学免疫学进展,2006,34(1):58-60. 被引量:9
  • 3杨明,陈作江,曹鑫,王志军,崔萱林.C群脑膜炎球菌多糖纯化方法的改进[J].微生物学免疫学进展,2006,34(4):27-29. 被引量:4
  • 4孟春,盛军,彭臻菲,彭煦,郭养浩.BSA免疫动物过程中抗原抗体亲和动力学特性的研究[J].免疫学杂志,2007,23(2):155-158. 被引量:3
  • 5Campagne G,Schuchat A,Djibo S,et al.Epidemiology of bacterial meningitis in Niamey,Niger,1981-1996[J].Bull World Health Organ,1999,77(6):499-508.
  • 6林云,李冶珊,高华,等.火箭免疫电泳法定量检测4价脑膜炎球菌多糖疫苗中C群脑膜炎球菌多糖含量的方法学验证[J].国际生物制品学杂志,2008,31(6):245-248.
  • 7国家食品药品监督管理局药品审评中心.GPH 1-1生物制品质量控制分析方法验证技术审评一般原则[S].2008-09-04.
  • 8CHANG Q,TZENG Y L,STEPHENS D S.Meningococcal disease:changes in epidemiology and prevention[J].Clin Epidemiol,2012,4(9):237-245.
  • 9STEPHENS D S,GREENWOOD B,BRANDTZAEG P.Epidemic meningitis,meningococcaemia,and Neisseria meningitidis[J].Lancet,2007,369(6):2196-2210.
  • 10REYES F,OTERO O,CUELLO M,et al.Development of four sandwich ELISAs for quantitation of capsular polysaccharides from Neisseria meningitidis serogroups A,C,W and Y in multivalent vaccines[J].J Immunol methods,2014,407(5):58-62.

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部